APVO SEC Filing News — Aptevo Therapeutics Inc.

Latest SEC filings for Aptevo Therapeutics Inc. (APVO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase …
Sector: Healthcare Industry: Biotechnology Market Cap: $2.9M CIK: 1671584
20
Total Filings
0
Bullish Classifications
0
Bearish Classifications
10
Insider Transactions
9
Material Events (8-K)
1
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Aptevo Therapeutics Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
APVO Filing Activity Snapshot 2026-06-30 — 2026-10-14
Insider Transactions (Form 4)
0 buys vs 0 sells
Insider buying and selling activity is balanced in this period.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Aptevo Therapeutics Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 10 option exercise. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Option exercise ×10
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Harsanyi Zsolt (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 — —
M Option exercise derivative · Restricted Stock Unit 400 — —
Filing: Form 4 (Insider Transaction) Insider: Harsanyi Zsolt (Director) Shares: 400
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Lamothe Jeffrey G. (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 961 — —
M Option exercise derivative · Restricted Stock Unit 961 — —
Filing: Form 4 (Insider Transaction) Insider: Lamothe Jeffrey G. (Director, President and CEO) Shares: 961
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Taylor Daphne (SVP, CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 638 — —
M Option exercise derivative · Restricted Stock Unit 638 — —
Filing: Form 4 (Insider Transaction) Insider: Taylor Daphne (SVP, CFO) Shares: 638
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Kwon SoYoung (SVP, GC, BD & Corp Affairs) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 638 — —
M Option exercise derivative · Restricted Stock Unit 638 — —
Filing: Form 4 (Insider Transaction) Insider: Kwon SoYoung (SVP, GC, BD & Corp Affairs) Shares: 638
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Grant Grady III (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 — —
M Option exercise derivative · Restricted Stock Unit 400 — —
Filing: Form 4 (Insider Transaction) Insider: Grant Grady III (Director) Shares: 400
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

White Marvin L (Director, Executive Chair) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1 — —
M Option exercise 1,666 — —
F Tax withholding on vested shares 406 $4.07 $1.7K
M Option exercise derivative · Restricted Stock Unit 1 — —
M Option exercise derivative · Restricted Stock Unit 1,666 — —
Filing: Form 4 (Insider Transaction) Insider: White Marvin L (Director, Executive Chair) Shares: 2,073
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Abdun-Nabi Daniel (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 — —
M Option exercise derivative · Restricted Stock Unit 400 — —
Filing: Form 4 (Insider Transaction) Insider: Abdun-Nabi Daniel (Director) Shares: 400
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Kunz Barbara Lopez (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 — —
M Option exercise derivative · Restricted Stock Unit 400 — —
Filing: Form 4 (Insider Transaction) Insider: Kunz Barbara Lopez (Director) Shares: 400
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Niederhuber John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 400 — —
M Option exercise derivative · Restricted Stock Unit 400 — —
Filing: Form 4 (Insider Transaction) Insider: Niederhuber John (Director) Shares: 400
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-08-10

APVO insider Form 4 filed for equity award, exercise, or tax withholding

Huebner Dirk (SVP, CMO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 638 — —
F Tax withholding on vested shares 156 $4.07 $634.92
M Option exercise derivative · Restricted Stock Unit 638 — —
Filing: Form 4 (Insider Transaction) Insider: Huebner Dirk (SVP, CMO) Shares: 794
View on SEC EDGAR → Open Filing Document →
Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for Aptevo Therapeutics Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-24

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-23

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-03

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-21

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-14

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-13

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-27

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-30

APVO filed 8-K — material company event

Aptevo Therapeutics Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Aptevo Therapeutics Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-14

APVO filed Quarterly Report (10-Q)

Aptevo Therapeutics Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Aptevo Therapeutics Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on APVO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — APVO SEC Filings

More Tools for APVO

APVO Full Stock Analysis APVO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper APVO analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the APVO stock analysis page.

APVO Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer